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Introduction: High-dose chemotherapy (HDC) followed by
auto-HCT can be performed in the outpt setting in selected
pts and may be as safe and more cost effective than in the
inpt setting. We evaluated the role of HCT-CI on the charac-
teristics and outcomes of pts with MMwho underwent auto-
HCT in both inpt and outpt settings between January 2008
and December 2012 at our institution.
Methods: We identiﬁed a total of 1046 pts, with 669 trans-
planted as inpts and 377 as outpts. Primary endpoints were
incidence of unscheduled admissions, treatment-related
mortality (TRM), grade 2-4 adverse events (AEs), deﬁned by
the National Cancer Institute’s Common Terminology
Criteria, version 4, and average cost of auto-HCT in both inpt
and outpt groups. Secondary endpoints were overall
response (OR) rates, progression-free survival (PFS), and
overall survival (OS).
Results: Median age at auto-HCT was 62 (range, 31-82) in
inpts and 58 (range, 34-78) years in outpts, (p<0.001).
HCT-CI score was 3 in 55% inpts vs 45% outpts (p¼.003).
There was no signiﬁcant difference in baseline cytogenetic
abnormalities, serum LDH or ISS stage II/III between the 2
groups. Forty-four (6.6%) inpts and 7 (2%) outpts had serum
creatinine of 2 mg/dL (p¼<0.001). Twenty-nine percent
of inpts vs. 21% of outpts had relapsed disease at auto-HCT
(p¼0.02). Median follow up in inpts vs. outpts was 14 and
15 months, respectively. One-hundred day TRM was 1.5% inFigure 1. 2-Year Progression Free Survivalinpts vs. 0.3% in outpts (p¼0.09). Grade 2-4 AEs were seen
in 552 (83%) inpts vs. 277 (73%) outpts (p¼0.001); grade 3-
4 in 359 (54%) inpts vs. 163 (43%) outpts (p¼0.001); and
grade 4 in 19 (3%) inpts vs. 6 (2%) outpts (p¼0.2). OR rates
were signiﬁcantly better in outpts, with 364 (96.5%) outpts
with PR vs. 599 (89%) inpts (p<0.001). Subsequent un-
scheduled hospitalizations were required in 208 (55%)
outpts, with neutropenic or non-neutropenic fever being
the most common reason (157 pts: 42%). On multivariate
analyses, an HCT-CI score of >2 and relapsed disease at
auto-HCT were associated with increased incidence of
unscheduled hospitalization. Outpts had signiﬁcantly
longer 2-year PFS (60% vs. 50%, p¼0.005, HR 0.7, 95% CI 0.6-
0.9) (Figure 1) and OS (83% vs. 77%, p¼0.01, HR 0.6, 95% CI
04-0.9) (Figure 2). The average cost of auto-HCT from the
date of original consult to day +30 was $416,154 for inpts
and $292,572 for outpts.
Discussion: In this study, pts selected for auto-HCT in the
outpt setting were younger, had a lower HCT-CI score and a
signiﬁcantly better renal function at diagnosis. A lower HCT-
CI score and auto-HCT in ﬁrst remission predict a lower risk
of unscheduled hospitalization, with a cost savings of
approximately $125,000 for those who received auto-HCT in
the outpt setting. Appropriately selected pts with MM can
safely undergo auto-HCT in the outpt setting without any
signiﬁcant increase in toxicity or TRM, and a signiﬁcant
decrease in transplant costs.116
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